Treating CLL With Bruton's Tyrosine Kinase Inhibitors

Choosing Between Venetoclax or BTK Inhibitors in Frontline CLL

During a live virtual event, Javier Pinilla-Ibarz, MD, PhD, discussed treatment options for chronic lymphocytic leukemia including ibrutinib, acalabrutinib, and venetoclax with obinutuzumab.

Part 2: Supporting Data for Ibrutinib-Based Regimens in Frontline CLL

During a live virtual event, Jose Sandoval Sus, MD, discussed with participating physicians frontline treatment options for patients with chronic lymphocytic leukemia, with questions by Targeted Oncology.

Part 1: Sandoval Sus Discusses Recommended Treatments for a Patient With CLL

During a live virtual event, Jose Sandoval Sus, MD, discussed with participating physicians frontline recommended treatment options for patients with chronic lymphocytic leukemia based on a case scenario, with questions by Targeted Oncology.

Part 2: Venetoclax and PI3K Inhibition for Relapsed/Refractory CLL

During a live virtual event, Danielle Brander, MD, discussed with participating physicians second-line treatment options for patients with chronic lymphocytic leukemia, with questions guided by Targeted Oncology.

Part 1: BTK Inhibitors for CLL in the Second Line

During a live virtual event, Danielle Brander, MD, discussed with participating physicians second-line treatment options for patients with chronic lymphocytic leukemia, with questions guided by Targeted Oncology.

Part 3: Considerations for Venetoclax-Based Therapy in Frontline CLL

During a live virtual event, Sameer A. Parikh, MBBS, discussed with participating physicians frontline treatment options in patients with chronic lymphocytic leukemia.

Part 2: BTK Inhibitor Options for Frontline CLL

During a live virtual event, Sameer A. Parikh, MBBS, discussed with participating physicians frontline treatment options of BTK inhibitors in patients with chronic lymphocytic leukemia.

Part 1: Frontline Treatment Options for CLL by Risk

During a live virtual event, Sameer A. Parikh, MBBS, discussed with participating physicians the treatment options for patients with chronic lymphocytic leukemia in the front-line setting by risk assessment.